Vaccine to prevent repeat Staph (Staphylococcus aureus) infections
Official title: Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease
Funded at Abvacc, INC. · NIH-11285431 · Data updated 2026-11-12
A multivalent toxoid vaccine called IBT-V02 aims to protect adults who get recurrent Staph aureus infections by neutralizing the bacteria's toxins and strengthening immune responses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abvacc, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | August 1, 2014 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $697,200 |
| NIH project number | 5R01AI111205-10 |
| Project ID | NIH-11285431 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (21 years and older) with a history of recurrent Staphylococcus aureus skin and soft tissue infections or frequent ER visits for staph infections would be the most likely candidates.
✕Less likely to help
Children under 21, people with infections not caused by Staphylococcus aureus, or those with conditions that prevent vaccine responses (severe immunosuppression) may not benefit.
What this research studies
This project is developing a multicomponent "toxoid" vaccine (IBT-V02) designed to block Staph aureus toxins and boost antibody and T‑cell responses that help control infection. The team has tested the vaccine in animal models, including models of first-time and recurrent skin and soft tissue infections, and is moving the candidate toward advanced development. The approach focuses on toxin neutralization rather than only targeting bacterial surface proteins, because previous surface-antigen vaccines failed in human trials. If development proceeds, the program may include clinical testing at company or partner clinical sites.
Why it matters
Potential benefit: If successful, the vaccine could reduce repeat Staph skin infections, lower hospital or ER visits, and cut the need for antibiotics.
How similar studies have gone: Prior vaccines targeting staph surface antigens failed in human trials, but preclinical work with this multivalent toxoid vaccine has shown protection in animal and recurrent infection models, while human efficacy is still unproven.
Where this research is happening
-
Abvacc, INC.
Rockville, United States Active
Researchers
- Principal investigator: Aman, M Javad — Abvacc, INC.
- Study coordinator: Aman, M Javad
Related research
Other NIH-funded projects on the same topics.
-
Multimodal antibody therapy to treat Staphylococcus aureus bloodstream infections
A hospital-focused immunotherapy approach uses a mix of antibodies to help fight blood infections from Staphylococcus aureus by blocking immune evasion and bacterial growth.
-
Monoclonal antibody cocktail to treat Marburg virus disease
A new antibody-based treatment approach is being developed to help people infected with Marburg virus, using a combination of two targeted antibodies.
-
Treatment for Marburg Virus Disease using Monoclonal Antibodies
This study is testing a new treatment made from special antibodies to help people with Marburg Virus Disease, aiming to make it safer and more effective for those who are affected by this serious illness.
-
Developing a treatment to protect healthcare workers from Marburg virus outbreaks
This study is working on a new treatment to help protect healthcare workers and first responders from the Marburg virus, which can be very dangerous, by using special antibodies that can keep them safe during outbreaks.
-
Creating a vaccine to protect against Marburg virus disease
This study is working on a new vaccine to help protect people from Marburg virus disease, which currently has no approved vaccines or treatments, by creating a special ingredient that boosts the immune response while keeping it safe and effective.
-
Understanding immune responses to improve vaccine effectiveness against Staphylococcus aureus infections
This study is looking at how our immune system fights off a bacteria called Staphylococcus aureus, which can cause serious infections, to help improve vaccines and treatments for people who might get these infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.